Melbourne University and Bio Farma to Jointly Develop Vaccine Adjuvant
News Dec 07, 2012
Melbourne University has announced an agreement with Indonesian vaccine maker Bio Farma to develop a vaccine delivery system that can boost the vaccine effectiveness for a range of infectious diseases, including Hepatitis C, Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemopilus influenza type-B.
"Bio Farma is proud to collaborate with the University of Melbourne. This agreement will surely give us an opportunity to enhance our research capacity," said Iskandar, the President Director of Bio Farma.
Iskandar expressed hope in the future of the collaboration on a vaccine delivery system to boost vaccine effectiveness (vaccine adjuvant) which would lead into a real contribution in the prevention of communicable disease in the world.
Under the proposed arrangement, Melbourne University receives research funding to further evaluate and develop a proof of concept.
The research agreement was facilitated by UoM Commercial Ltd, the University's Commercial Engagement Service company and signed on 3 September 2012.
According to Iskandar, the collaboration with Melbourne University will run for 18 months as presently the research is still in the level of proof of concept.
Upon getting a result, the next step will be enhanced to a technology license level.
Professor James Angus, Dean of the Faculty of Medicine, Dentistry and Health Sciences at Melbourne University, remarked that he was delighted to be collaborating with the Board of Bio Farma and its scientific team in relation to developing a novel vaccine platform.
The vaccine platform would lead to better and more efficacious vaccines against infectious diseases. "This agreement reflects the desire for research at the University of Melbourne to be translated into impact and recognizes the importance of collaboration with leading vaccine companies to achieve this goal," said Professor Angus.
Research led by Professor David Jackson's team in the Department of Microbiology and Immunology at the University of Melbourne has shown that a synthetic TLR2 agonist-based adjuvant can enhance immunity and protect animals from viral and bacterial infections.
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018